Cargando…
Carbonic anhydrases as biocatalysts : from theory to medical and industrial applications /
Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes, present throughout most living organisms and encoded by five evolutionarily unrelated gene families. The Carbonic Anhydrases as Biocatalysts: From Theory to Medical and Industrial Applications presents information on the growing in...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Elsevier,
[2015]
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover; Title Page; Copyright Page; Table of contents; List of Contributors; Preface; Part 1
- Introduction; Chapter 1
- Carbonic Anhydrases: An Overview; 1.1
- Carbonic anhydrase families; 1.2
- Catalytic features; 1.3
- CA inhibition and activation; 1.4
- Biomedical applications of the CAs; 1.5
- Biotechnological applications of the CAs; References; Part 2
- Carbonic Anhydrasesas Drug Targets; Chapter 2
- Human Carbonic Anhydrases: Catalytic Properties, Structural Features, and Tissue Distribution; 2.1
- Introduction; 2.2
- hCAs' structural features; 2.3
- hCAs' catalytic features.
- 2.4
- hCAs' tissue distribution and their role as drug targetsReferences; Chapter 3
- Carbonic Anhydrase I; 3.1
- Introduction; 3.2
- Structure of CA I; 3.3
- Tissue localization and physiological functions; 3.4
- CA I as pharmacological target; 3.5
- CA I inhibitors; 3.6
- CA I activators; 3.7
- Conclusions and perspectives; Acknowledgment; References; Chapter 4
- Carbonic Anhydrase II as Target for Drug Design; 4.1
- Introduction; 4.2
- Biochemical properties, genetic relationship with the other cytosolic isoforms, and 3D structure of hCA II; 4.3
- hCA II inhibitors.
- 4.4
- Antiglaucoma agents4.4.1
- First-generation inhibitors; 4.4.2
- Second-generation inhibitors: topically acting sulfonamides; 4.4.3
- Third-generation inhibitors; 4.4.4
- Dithiocarbamates and xanthates as topically acting antiglaucoma CAIs targeting hCA II; 4.5
- Diuretics with CA inhibitory properties; 4.6
- Agents for the management of altitude sickness; 4.7
- Various pharmacological actions connected with CA II inhibition: serendipity or off-targeting with impressive efficacy?; 4.8
- CA II inhibitors in the management of tumors?
- 4.9
- New strategies to design CA II-selective inhibitors4.10
- CA II activation; 4.11
- Conclusions; References; Chapter 5
- Carbonic Anhydrase III; 5.1
- Introduction; 5.2
- Discovery of CA III; 5.3
- Physiological role of CA III; 5.4
- Molecular characterization of CA III; 5.5
- Catalytic properties and proton transfer of CA III; 5.6
- CA III as a biomarker: role in disease states; 5.7
- CA III as a drug target; Acknowledgment; References; Chapter 6
- Carbonic Anhydrase IV; 6.1
- Introduction; 6.2
- Genomic organization and chromosomal localization of human CA IV.
- 6.3
- Cloning and molecular characterization of human CA IV6.4
- Structure/function: the role of disulfide bonds; 6.5
- Characterization of catalytic properties of human CA IV and its inhibition by sulfonamide inhibitors; 6.6
- Expression of CA IV in different tissues; 6.7
- Physiological functions of CA IV; 6.7.1
- Kidney function; 6.7.2
- Neuronal function; 6.7.3
- Eye function; 6.7.4
- Skeletal and cardiac muscle function; 6.7.5
- CA IV functions in metabolons; 6.7.6
- The role of CA IV in the taste of carbonation; 6.7.7
- Disease-causing mutations in CA IV; 6.7.8
- Kidney disease.
- 6.7.9
- Environmental factors contributing to RP-17 associated with CA IV mutations.